Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 4
2000 2
2001 5
2002 1
2003 3
2005 1
2006 1
2007 3
2008 3
2009 1
2010 1
2013 1
2014 5
2015 5
2017 2
2019 2
2020 3
2021 3
2022 5
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Results by year
Filters applied: . Clear all
Page 1
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: wiederschain d. Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23. Nature. 2022. PMID: 35197632
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karikó K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D. Hotz C, et al. Among authors: wiederschain d. Sci Transl Med. 2021 Sep 8;13(610):eabc7804. doi: 10.1126/scitranslmed.abc7804. Epub 2021 Sep 8. Sci Transl Med. 2021. PMID: 34516826
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Martin TG, et al. Among authors: wiederschain d. Cells. 2019 Nov 26;8(12):1522. doi: 10.3390/cells8121522. Cells. 2019. PMID: 31779273 Free PMC article. Review.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A. Kassem S, et al. Among authors: wiederschain d. Blood. 2022 Feb 24;139(8):1160-1176. doi: 10.1182/blood.2021012448. Blood. 2022. PMID: 35201323
Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo.
Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, Cantwell J, Luu C, Cornella-Taracido I, Harrington E, Fekkes P, Lei H, Fang Q, Digan ME, Burdick D, Powers AF, Helliwell SB, D'Aquin S, Bastien J, Wang H, Wiederschain D, Kuerth J, Bergman P, Schwalb D, Thomas J, Ugwonali S, Harbinski F, Tallarico J, Wilson CJ, Myer VE, Porter JA, Bussiere DE, Finan PM, Labow MA, Mao X, Hamann LG, Manning BD, Valdez RA, Nicholson T, Schirle M, Knapp MS, Keaney EP, Murphy LO. Dowdle WE, et al. Among authors: wiederschain d. Nat Cell Biol. 2014 Nov;16(11):1069-79. doi: 10.1038/ncb3053. Epub 2014 Oct 19. Nat Cell Biol. 2014. PMID: 25327288
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T. Mandel I, et al. Among authors: wiederschain d. J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859. J Immunother Cancer. 2022. PMID: 36096532 Free PMC article.
Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: wiederschain d. Nature. 2022 Apr;604(7905):E13. doi: 10.1038/s41586-022-04652-x. Nature. 2022. PMID: 35332336 No abstract available.
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD, Stack EC, Buggé JA, Hu C, McGrath L, Mueller A, Wong M, Klebanov B, Rahman T, Kaufman R, Fregeau C, Spaulding V, Priess M, Legendre K, Jaffe S, Upadhyay D, Singh A, Xu CA, Krukenberg K, Zhang Y, Ezzyat Y, Saddier Axe D, Kuhne MR, Meehl MA, Shaffer DR, Weist BM, Wiederschain D, Depis F, Gostissa M. Weaver JD, et al. Among authors: wiederschain d. Oncoimmunology. 2022 Nov 4;11(1):2141007. doi: 10.1080/2162402X.2022.2141007. eCollection 2022. Oncoimmunology. 2022. PMID: 36352891 Free PMC article.
PTEN-deficient cancers depend on PIK3CB.
Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C. Wee S, et al. Among authors: wiederschain d. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28. Proc Natl Acad Sci U S A. 2008. PMID: 18755892 Free PMC article.
52 results